TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01066026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid with metallic cannula or standard needle.
Description: The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid with metallic cannula or standard needle.
Description: The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~* In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~* In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injected with the new tool.
Description: hyaluronic acid with metallic cannula.
Study: NCT00890305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours).
Study: NCT00094822

Intervention type: OTHER
Intervention: PI Discretion
Description: PI Discretion

Intervention type: OTHER
Intervention: PI Discretion
Description: PI Discretion
Study: NCT04286113

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle management
Description: Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
Study: NCT00609336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreatic surgical procedure
Description: Undergo pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo therapeutic conventional surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03206515

Intervention type: DEVICE
Group type: OTHER
Intervention: 18F Peel-Way Sheath
Description: Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath

Intervention type: DEVICE
Group type: OTHER
Intervention: 18F access sheath with a suction-evacuation function
Description: Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
Study: NCT03991286

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin 8 mg
Description: experimental

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo pill
Study: NCT03553537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: DOX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: DOX
Study: NCT01216761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine tincture
Description: Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: 10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: 10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone iodine
Description: 10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
Study: NCT02130154

Intervention type: OTHER
Intervention: 18-FDG PET CT scan and 123I-MIBG SPECT scan

Intervention type: OTHER
Intervention: 18-FDG PET CT scan and 123I-MIBG SPECT scan
Study: NCT01241019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia
Description: TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
Study: NCT01450956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be given at a concentration of 2% through oxygenator during CPB

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Patients will receive only oxygen and air through oxygenator
Study: NCT03937258

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Probenecid
Description: In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
Study: NCT04176744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uni- and bilateral magnetic phrenic nerve stimulation
Description: Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
Study: NCT01287481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress and Emotions
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thoughts and Behaviors
Description: Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Study: NCT03483207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MVT with failure of anticoagulation therapy
Description: patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MVT with failure of anticoagulation therapy
Description: patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin \&warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
Study: NCT00891839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine at 90 mg/m\^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients receive 375 mg/m\^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
Study: NCT04048343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection every 4 weeks
Study: NCT03052413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrafol
Description: Eligible subjects will receive Nutrafol® to take daily for 180 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Eligible subjects will receive Placebo to take daily for 180 days
Study: NCT03553537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4mg/m² iv on day 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4mg/m² iv on day 6
Study: NCT02668250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OPTI-AGED
Description: OPTI-AGED is composed of a multi-parametric optimization strategy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients receive the usual care.
Study: NCT02395913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfolase capsule (100mg)
Description: Surfolase capsule one capsule twice one days fasting administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T1)
Description: one tablet once one days fasting administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T3)
Description: one tablet once one days fasting administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR (200mg, T4)
Description: one tablet once one days fasting administration.
Study: NCT02023710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study: NCT01287481

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain and Body
Description: Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
Study: NCT03224481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic reminder
Description: The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
Study: NCT03915236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MON4STRAT Strategy
Description: Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
Study: NCT01543139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate+Cytidine-+Creatine-
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate+Cytidine-
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: Valproate: Week0-8: 300mg/day
Study: NCT01315847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Description: Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telcagepant
Description: Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-4232
Description: Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-4232
Description: Single intravenous doses of \~300 MBq \[11C\]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
Study: NCT00234208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medical thoracoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple chest tube drainage
Study: NCT03971500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiPlatelet therapy
Description: AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
Study: NCT02023710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
Study: NCT02704507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: topical application nightly to half the face for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tretinoin
Description: topical application nightly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin
Description: topical application nightly for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Emollient
Description: topical application nightly to half the face for 4 weeks
Study: NCT00767559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 5 mg beginning the night before surgery, followed by 5 mg the PM of surgery\*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux:
Description: 2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day\*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery.
Study: NCT02541461

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic gastrectomy
Description: (1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic gastrectomy
Description: (1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
Study: NCT03251222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal aplication of dexmedetomidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: Intranasal aplication of 0.9% NaCl